Glutathione trisulfide
Glutathione trisulfide (GSSSG) is an orally active, blood-brain barrier permeable neuroprotective agent. Glutathione trisulfide inactivates intracellular tyrosinase, regulates the expression of Cars2, Cbs, MITF and TYR, inhibits α-MSH (HY-P0252)-induced melanogenesis, and restores intracellular persulfide levels reduced by α-MSH. Glutathione trisulfide scavenges free radicals, quenches ROS, reduces Paclitaxel (HY-B0015)-induced superoxide production, upregulates the expression of antioxidant protein genes, and inhibits oxidative stress-induced cell death. Glutathione trisulfide promotes ERK1/2 activation, prevents NF-κB p65 activation, inhibits TAK1 phosphorylation, reduces pro-inflammatory cytokine expression, and blocks microglial activation. Glutathione trisulfide can be used in research related to dry age-related macular degeneration, inflammation-associated eye diseases, Alzheimer's disease, Parkinson's disease, etc.
For research use only. We do not sell to patients.
- CAS No.: 32607-79-7
- Formula: C20H32N6O12S3
- Molecular Weight:644.69
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
|
IL-6 |
IL-1β |
Cars2 |
Cbs |
MITF |
TYR |
ERK1 |
ERK2 |
NF-κB |
p65 |
TAK1 |
In Vitro
Glutathione trisulfide (GSSSG) (25-100 μM; 30 min pretreatment, 24 h α-MSH (HY-P0252) incubation) is non-cytotoxic to B16-F0 cells at 25 μM and 50 μM following 30 min pretreatment and 24 h α-MSH incubation, while 100 μM causes a modest non-significant viability reduction[1].
Glutathione trisulfide (25-50 μM; 30 min pretreatment, 24 h α-MSH incubation) potently suppresses α-MSH-induced melanin production in B16-F0 cells[1].
Glutathione trisulfide (25-50 μM; 30 min pretreatment, 24 h α-MSH incubation) dose-dependently downregulates Mitf and TYR gene expression in α-MSH-induced B16-F0 cells[1].
Glutathione trisulfide (25-50 μM; 30 min pretreatment, 24 h α-MSH incubation) significantly upregulates Cars2 and Cbs gene expression in α-MSH-induced B16-F0 cells[1].
Glutathione trisulfide (25-50 μM; 30 min pretreatment, 24 h α-MSH incubation) significantly restores α-MSH-reduced intracellular persulphide levels in B16-F0 cells[1].
Glutathione trisulfide (50 μM; 30 min pretreatment, 24 h α-MSH incubation) significantly inactivates intracellular tyrosinase activity in α-MSH-induced B16-F0 cells[1].
Glutathione trisulfide (0.1-100 μM; 24 h) protects SH-SY5Y cells from MPP+-induced cell death[3].
Glutathione trisulfide (0.1-2 mM; 30 min) exhibits dose-dependent antioxidant radical-scavenging activity in a cell-free DPPH assay, with up to 65% scavenging activity at 2 mM[1].
Glutathione trisulfide (10-30 μM; 30 minutes) attenuates Paclitaxel-induced superoxide production in cultured murine primary cortical neurons[5].
Glutathione trisulfide (25-200 µM; 6 h) is non-toxic to mouse primary Müller cells and BV-2 microglial cells at concentrations up to 100 µM, while 200 µM reduces Müller cell viability[2].
Glutathione trisulfide (25-200 µM; 1 h pre-incubation, 6 h or 24 h LPS stimulation) dose-dependently inhibits LPS-induced upregulation of IL-6 and Ccl2 mRNA expression and protein secretion in mouse primary Müller cells, with significant effects at concentrations of 100 and 200 µM[2].
Glutathione trisulfide (200 µM; 1 h pre-incubation, 30 or 60 min LPS stimulation) inhibits LPS-induced phosphorylation of TAK1 (Ser412) in mouse BV-2 microglial cells at 30 and 60 minutes post-LPS stimulation[2].
Glutathione trisulfide (25-200 µM; 1 h pre-incubation, 6 h or 24 h LPS stimulation) dose-dependently inhibits LPS-induced upregulation of TNF-α, Ccl2, IL-6, and IL-1β mRNA expression, as well as TNF-α, Ccl2, and IL-6 protein secretion in mouse BV-2 microglial cells, with significant effects starting at 25 µM for some targets[2].
Glutathione trisulfide (500 nM; 1 hour) prevents Paclitaxel (HY-B0015)-induced axonal degeneration and mitochondrial fragmentation in cultured murine primary DRG neurons by restoring axonal elongation and preserving axonal mitochondrial integrity[5].
Glutathione trisulfide (10 μM; 24 hours) does not alter the anti-tumor cytotoxic effect of 2 μM Paclitaxel on human breast cancer MDA-MB-231 cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:B16-F0 murine melanoma cells
-
Concentration:25 μM; 50 μM; 100 μM
-
Incubation Time:30 min (pretreatment); 24 h (α-MSH incubation)
-
Result:Caused no reduction in B16-F0 cell viability at 25 μM and 50 μM.
Caused a modest, non-statistically significant reduction in cell viability at 100 μM.
-
Cell Line:α-MSH-induced B16-F0 murine melanoma cells
-
Concentration:25 μM; 50 μM
-
Incubation Time:30 min (pretreatment); 24 h (α-MSH incubation)
-
Result:Downregulated the expression of melanogenesis-related genes Mitf and TYR in a dose-dependent manner.
Induced statistically significant reductions in Mitf and TYR expression at 25 μM and 50 μM relative to α-MSH-only treated cells.\nSignificantly upregulated the expression of persulphide synthesis-related genes Cars2 and Cbs in α-MSH-treated cells.
Induced statistically significant increases in Cars2 and Cbs expression at both 25 μM and 50 μM concentrations.
-
Cell Line:mouse BV-2 microglial cells
-
Concentration:25-200 µM
-
Incubation Time:1 h pre-incubation; 6 h LPS stimulation (mRNA); 1 h pre-incubation; 6 h or 24 h LPS stimulation (protein)
-
Result:Significantly inhibited LPS-induced TNF-α mRNA expression at 50, 100, and 200 µM.
Significantly inhibited LPS-induced Ccl2 mRNA expression at 200 µM.
Significantly inhibited LPS-induced IL-6 mRNA expression at 50, 100, and 200 µM.
Significantly inhibited LPS-induced IL-1β mRNA expression at 25, 50, 100, and 200 µM.
Significantly inhibited LPS-induced TNF-α secretion at 200 µM.
Significantly inhibited LPS-induced Ccl2 secretion at 200 µM.
-
Cell Line:mouse BV-2 microglial cells
-
Concentration:200 µM
-
Incubation Time:1 h pre-incubation; 30 or 60 min LPS stimulation
-
Result:Significantly inhibited LPS-induced TAK1 phosphorylation (Ser412) at 30 minutes post-stimulation.
Significantly inhibited LPS-induced TAK1 phosphorylation (Ser412) at 60 minutes post-stimulation.
-
Cell Line:human neuroblastoma SH-SY5Y cells
-
Concentration:0.1-100 μM
-
Incubation Time:24 h
-
Result:Significantly increased cell viability relative to MPP+-treated cells at all tested concentrations.
-
Cell Line:human breast cancer MDA-MB-231 cells
-
Concentration:10 μM
-
Incubation Time:24 hours
-
Result:Resulted in 48.3% viable cells, compared to 44.9% viable cells with Paclitaxel alone.
Showed no significant difference from Paclitaxel-only group via statistical equivalence testing (10% margin), with a mean difference of 0.034 and 90% confidence interval of -0.280 to 0.357.
In Vivo
Glutathione trisulfide (200 mg/kg; i.p.; daily; 4 days) prevents post-ischemic spinal cord injury-induced paraplegia in mice, while maintaining a 100% survival rate[3].
Glutathione trisulfide (50 mg/kg/day; oral gavage; daily; 28 days) ameliorates Paclitaxel-induced mechanical allodynia in male C57BL/6J mice by preserving unmyelinated axon integrity, reducing mitochondrial swelling, and upregulating antioxidant signaling in peripheral sensory neurons[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar rats (8-10 weeks old)[2]
-
Dosage:15 nmol/eye; 60 nmol/eye
-
Administration:intravitreal; single co-administration with LPS
-
Result:Significantly decreased LPS-induced upregulation of IL-6 mRNA in rat retinas at 15 nmol/eye dose, but did not significantly affect IL-1β or Ccl2 mRNA upregulation.
Significantly attenuated LPS-induced upregulation of IL-6, IL-1β, and Ccl2 mRNA in rat retinas at 60 nmol/eye dose.
Significantly reduced LPS-induced accumulation of Iba1-immunopositive microglia in rat retinas at 60 nmol/eye dose, lowering density from ~900 cells/mm2 (LPS alone) to ~700 cells/mm2.
Did not affect baseline microglial density when administered alone.
-
Animal Model:unspecified strain[3]
-
Dosage:200 mg/kg
-
Administration:i.p.; daily; 4 days
-
Result:Maintained BMS scores >6 in all 4 treated mice at 24, 48, and 72 hours post-SCI, with 0/4 developing paraplegia.
Achieved a 100% survival rate (4/4 mice) at 72 hours post-SCI.
-
Animal Model:C57BL/6J (male, 6-7 weeks old, Paclitaxel-induced peripheral neuropathy)[5]
-
Dosage:50 mg/kg/day (behavioral/histological studies); 50 mg/kg (tissue distribution studies); 50 mg/kg (gene expression studies)
-
Administration:oral gavage; daily; 28 days (behavioral/histological studies); oral gavage; single dose (tissue distribution studies); oral gavage; single dose (gene expression studies)
-
Result:Ameliorated Paclitaxel-induced mechanical allodynia over 28 days, but did not alter thermal hyperalgesia.
Prevented Paclitaxel-induced loss of intraepidermal nerve fibers at 4 weeks.
Increased the ratio of unmyelinated axons in sciatic nerves compared to Paclitaxel-only mice; did not affect myelinated axon count or myelin thickness (G-ratio).
Reduced Paclitaxel-induced mitochondrial swelling in unmyelinated sciatic nerve axons, with a median mitochondrial cross-sectional area of 0.041 μm2.
Detected 34S-labeled form 2 hours after oral administration at concentrations of 415 pmol/mg protein in lumbar DRG, 518 pmol/mg protein in lumbar spinal cord, 142 pmol/mg protein in brain, 158 pmol/mg protein in liver, and 58 pmol/mL in plasma; 34S-labeled reactive sulfur species (GSSH, CysSSH, CysSSSCys) were >10-fold higher than endogenous 32S-containing counterparts in all tissues.
Upregulated mRNA expression of Nrf2-dependent antioxidant genes in lumbar DRG 2 hours after co-administration with Paclitaxel.
Chemical Information
-
CAS No. 32607-79-7
-
Molecular Weight 644.69
-
Formula C20H32N6O12S3
-
SMILES
[C@@H](NC(CC[C@@H](C(O)=O)N)=O)(C(NCC(O)=O)=O)CSSSC[C@H](NC(CC[C@@H](C(O)=O)N)=O)C(NCC(O)=O)=O
-
Synonyms
GSSSG
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Human pluripotent stem cell midbrain dopaminergic neuron differentiation
Human pluripotent stem cells are directed toward midbrain dopaminergic neurons by first inducing a neural floor-plate-like progenitor state, then patterning cells with ventralizing SHH signaling and midbrain/WNT-FGF cues, and finally maturing progenitors into neurons expressing dopaminergic markers such as TH, NURR1/NR4A2, PITX3, DAT/SLC6A3, VMAT2/SLC18A2, GIRK2/KCNJ6, FOXA2, LMX1A, and EN1. The main readouts are loss of pluripotency, acquisition of FOXA2+/LMX1A+ midbrain floor-plate progenitors, emergence of βIII-tubulin+/MAP2+ neurons, and production of TH+ dopaminergic neurons with molecular, dopamine-release, and electrophysiological features of midbrain dopaminergic identity.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Glutathione trisulfide
- 32607-79-7
- GSSSG
- Interleukin Related
- Tyrosinase
- ERK
- Microphthalmia Associated Transcription Factor (MITF)
- Reactive Oxygen Species (ROS)
- NF-κB
- ARPE-19 cells
- MDA-MB-231 cells
- BV-2 microglial cells
- murine primary cortical neurons
- primary mouse RPE cells
- murine primary DRG neurons
- B16-F0 cells
- SH-SY5Y cells
- primary human RPE cells
- mouse primary Müller cells
- Inhibitor
- inhibitor
- inhibit